Molecular imaging gets R&D boost
The National Cancer Institute recognized the emerging role of molecular imaging with a three-year contract aimed at the development of agents to diagnose and treat cancer. The $2.8 million contract was awarded to Barnes Jewish Hospital and Washington
The National Cancer Institute recognized the emerging role of molecular imaging with a three-year contract aimed at the development of agents to diagnose and treat cancer. The $2.8 million contract was awarded to Barnes Jewish Hospital and Washington University School of Medicine in St. Louis. The development and testing of novel agents will be done in combination with advanced imaging systems. Academic researchers will collaborate with Philips Medical and Dow Chemical to create and evaluate contrast and therapeutic agents designed to seek out specific molecular targets. Kereos will develop and commercialize promising agents.
The contract includes the development of nuclear imaging technology and image analysis techniques aimed at enhancing image quality, as well as delivering quantitative information about disease. Specific goals include finding means for detecting and quantifying solid tumors noninvasively and earlier in their development by identifying sites in the body where new blood vessels are forming to feed tumors. The research will also seek therapeutic agents that can be administered directly to the site of growing tumors to disrupt angiogenesis and the means to assess the adequacy of treatment by quantifying the amount of therapy delivered to a tumor.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
